Posted by Michael Wonder on 29 Jul 2021
Advanz and private equity groups fined for 1,000 per cent drug price hike
29 July 2021 - Regulator penalises pharma company and buyout firms Cinven and Hg after NHS hit by ‘unfair’ rises.
In its latest assault on Big Pharma, the Competition and Markets Authority said Advanz and the buyout groups, which owned businesses that are now part of the pharma company, had charged “excessive and unfair prices” for liothyronine.
